- Home
- FC vs IKT Comparison
FC vs IKT Comparison
Compare FC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FC | IKT |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.2M | 240.1M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FC | IKT |
|---|---|---|
| Price | $22.17 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $26.00 | $5.00 |
| AVG Volume (30 Days) | 225.7K | ★ 1.0M |
| Earning Date | 04-01-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $267,067,000.00 | N/A |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.16 | $1.33 |
| 52 Week High | $24.70 | $2.37 |
Technical Indicators
Market Signals| Indicator | FC | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 55.41 |
| Support Level | $18.76 | $1.62 |
| Resistance Level | $24.27 | $1.88 |
| Average True Range (ATR) | 1.12 | 0.11 |
| MACD | -0.34 | 0.02 |
| Stochastic Oscillator | 47.29 | 78.12 |
Price Performance
Historical ComparisonAbout FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.